10.1016/S0891-5520(05)70392-5
10.1111/j.1749-6632.1971.tb30664.x
10.1128/mr.51.1.88-134.1987
10.1016/j.plasmid.2005.08.001
10.1016/0002-9343(93)90063-U
Performance standards for antimicrobial susceptibility testing 16th informational supplement. M100-S16. Clinical and Laboratory Standards Institute. 26(1) 116–121 Wayne PA USA (2006).
10.1016/S0924-8579(03)00154-7
10.1016/S1473-3099(02)00227-X
10.1016/S1473-3099(05)70243-7
10.1111/j.1469-0691.2003.00698.x
10.7326/0003-4819-144-5-200603070-00014
10.1128/JB.183.22.6525-6531.2001
10.1128/AAC.44.6.1549-1555.2000
10.1128/AAC.50.3.1001-1012.2006
10.1128/AAC.49.5.2070-2083.2005
10.1128/AAC.46.4.1147-1152.2002
10.1128/AAC.48.7.2637-2651.2004
10.1128/JB.183.8.2417-2424.2001
10.1128/AAC.45.1.349-352.2001
10.1016/j.diagmicrobio.2004.09.005
10.1128/AAC.47.10.3040-3045.2003
10.1016/S0140-6736(97)07324-8
10.1089/107662904323047790
10.1128/jb.179.8.2557-2566.1997
10.1128/AAC.50.2.428-438.2006
10.1016/0966-842X(96)10063-9
10.1128/AAC.48.1.275-280.2004
Zhu W WeigelL ClarkN McDougalL PatelM: Presented at: 46th Interscience Conference for Antimicrobial Agents and Chemotherapy. San Francisco CA USA 17–20 September 2006.
Centers for Disease Control and Prevention (CDC): Staphylococcus aureus resistant to vancomycin – United States, 2002. Morb. Mortal. Wkly Rep.51 , 565–567 (2002).
10.1093/infdis/163.6.1279
10.1016/S1473-3099(02)00369-9
10.1016/S0140-6736(01)05410-1
10.1128/AAC.46.10.3334-3336.2002
10.1128/JCM.43.10.5384-5387.2005
10.1128/JCM.44.2.595-597.2006
10.1016/j.ijantimicag.2006.05.030
10.1128/AAC.50.3.1079-1082.2006
10.1016/j.diagmicrobio.2006.05.009
O‘Neill AJ , LarsenAR, SkovR, Henriksen AS, Chopra I: Characterization of the Epidemic European Fusidic acid-resistant Impetigo Clone (EEFIC) of Staphylococcus aureus.J. Clin. Microbiol. (2007) (Epub ahead of print).
10.1016/j.amjmed.2006.01.004
10.1016/S0140-6736(06)68231-7
10.1016/j.mcp.2006.10.003
10.1111/j.1469-0691.2006.01403.x
10.1016/j.coph.2006.06.002
10.1128/JB.187.20.7161-7164.2005
10.1128/AAC.48.12.4762-4765.2004